← Sarepta Therapeutics overview

Sarepta Therapeutics vs Pharming Group NV: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Sarepta Therapeutics Inc (SRPT)

Q3 2026
▲2▼2

New CEO, FDA filing progress, but Elevidys safety overhang persists

  • New CEO brings turnaround credibility Sarepta named Michael Severino, a veteran biopharma executive, as CEO effective July 28, 2026, and granted him equity awards tied to a $17.74 exercise price. A fresh leader with a strong track record can improve execution and restore investor confidence, though the impact will take time to show.

    Leadership change is a major new event that can drive future value and investor sentiment.

  • FDA accepts applications to convert two DMD drugs to full approval The FDA accepted Sarepta's applications to convert accelerated approvals for AMONDYS 45 and VYONDYS 53 to traditional approvals, with a decision due February 2027. Success would strengthen the company's non-gene-therapy DMD franchise and reduce reliance on Elevidys, a key positive.

    This regulatory step could diversify revenue and lower concentration risk around Elevidys.

  • Elevidys sales collapse and safety restrictions remain Q2 revenue fell 34% as Elevidys sales dropped 65% to $98.1 million due to a shipment suspension for non-ambulatory patients. The FDA still restricts Elevidys to ambulatory patients and requires a boxed warning for fatal liver injury; new two-year data do not remove these limits, keeping a cloud over the key product.

    Elevidys is central to Sarepta's prospects, and its safety issues and sales decline are the main drag on the stock.

  • High short interest and low valuation reflect deep skepticism Short interest stands at 28.86% of the float, and the stock trades at about 0.9 times trailing sales versus 3.2 times for a rare-disease peer. While a low valuation can attract bargain hunters, heavy shorting signals that many investors doubt the company's ability to overcome Elevidys setbacks.

    Short interest and valuation show how the market is pricing the risks and can amplify volatility.

August 2026
▲2▼2

New CEO, FDA filing progress, but Elevidys safety overhang persists

  • New CEO brings turnaround credibility Sarepta named Michael Severino, a veteran biopharma executive, as CEO effective July 28, 2026, and granted him equity awards tied to a $17.74 exercise price. A fresh leader with a strong track record can improve execution and restore investor confidence, though the impact will take time to show.

    Leadership change is a major new event that can drive future value and investor sentiment.

  • FDA accepts applications to convert two DMD drugs to full approval The FDA accepted Sarepta's applications to convert accelerated approvals for AMONDYS 45 and VYONDYS 53 to traditional approvals, with a decision due February 2027. Success would strengthen the company's non-gene-therapy DMD franchise and reduce reliance on Elevidys, a key positive.

    This regulatory step could diversify revenue and lower concentration risk around Elevidys.

  • Elevidys sales collapse and safety restrictions remain Q2 revenue fell 34% as Elevidys sales dropped 65% to $98.1 million due to a shipment suspension for non-ambulatory patients. The FDA still restricts Elevidys to ambulatory patients and requires a boxed warning for fatal liver injury; new two-year data do not remove these limits, keeping a cloud over the key product.

    Elevidys is central to Sarepta's prospects, and its safety issues and sales decline are the main drag on the stock.

  • High short interest and low valuation reflect deep skepticism Short interest stands at 28.86% of the float, and the stock trades at about 0.9 times trailing sales versus 3.2 times for a rare-disease peer. While a low valuation can attract bargain hunters, heavy shorting signals that many investors doubt the company's ability to overcome Elevidys setbacks.

    Short interest and valuation show how the market is pricing the risks and can amplify volatility.

Latest
▲2▼2

New CEO, FDA filing progress, but Elevidys safety overhang persists

  • New CEO brings turnaround credibility Sarepta named Michael Severino, a veteran biopharma executive, as CEO effective July 28, 2026, and granted him equity awards tied to a $17.74 exercise price. A fresh leader with a strong track record can improve execution and restore investor confidence, though the impact will take time to show.

    Leadership change is a major new event that can drive future value and investor sentiment.

  • FDA accepts applications to convert two DMD drugs to full approval The FDA accepted Sarepta's applications to convert accelerated approvals for AMONDYS 45 and VYONDYS 53 to traditional approvals, with a decision due February 2027. Success would strengthen the company's non-gene-therapy DMD franchise and reduce reliance on Elevidys, a key positive.

    This regulatory step could diversify revenue and lower concentration risk around Elevidys.

  • Elevidys sales collapse and safety restrictions remain Q2 revenue fell 34% as Elevidys sales dropped 65% to $98.1 million due to a shipment suspension for non-ambulatory patients. The FDA still restricts Elevidys to ambulatory patients and requires a boxed warning for fatal liver injury; new two-year data do not remove these limits, keeping a cloud over the key product.

    Elevidys is central to Sarepta's prospects, and its safety issues and sales decline are the main drag on the stock.

  • High short interest and low valuation reflect deep skepticism Short interest stands at 28.86% of the float, and the stock trades at about 0.9 times trailing sales versus 3.2 times for a rare-disease peer. While a low valuation can attract bargain hunters, heavy shorting signals that many investors doubt the company's ability to overcome Elevidys setbacks.

    Short interest and valuation show how the market is pricing the risks and can amplify volatility.

Pharming Group NV (PHARM.AS)

Q3 2026
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.

August 2026
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.

Latest
▼3▲1

Pharming hit by guidance cut and CEO exit, offset by Joenja label wins

  • Q2 miss and $30M guidance cut Pharming's Q2 revenue of $90.2M missed estimates and full-year guidance was cut by $30M, mainly because legacy RUCONEST sales fell 10% on lower volume. Shares dropped 15% as investors re-priced slower growth. This is the core reason the stock is weaker.

    The guidance cut is the single biggest negative force behind the stock's move this period.

  • Securities investigation adds legal overhang Law firm Levi & Korsinsky is investigating whether Pharming failed to warn investors about RUCONEST competition and demand pressure before the Q2 miss. Such probes can lead to lawsuits, cost money and keep a cloud over the shares, weighing on sentiment.

    It is a new negative overhang that can affect the stock beyond the one-day drop.

  • Joenja expands in Japan and to young US children Joenja launched in Japan and won FDA approval for children aged 4-11 in the US, widening the patient pool for Pharming's growth drug. More eligible patients should lift future Joenja sales, the main offset to RUCONEST's decline.

    These approvals are the main positive counterweight to the weak RUCONEST story.

  • CEO exits abruptly, interim co-CEOs take over CEO Fabrice Chouraqui stepped down immediately after the board and he disagreed on strategy, with two executives named interim co-CEOs. Leadership churn creates uncertainty about execution just as the company needs to steady RUCONEST and grow Joenja, pressuring the shares.

    An abrupt CEO departure is a fresh governance risk that can hold the stock back.